JP2010537990A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537990A5
JP2010537990A5 JP2010522982A JP2010522982A JP2010537990A5 JP 2010537990 A5 JP2010537990 A5 JP 2010537990A5 JP 2010522982 A JP2010522982 A JP 2010522982A JP 2010522982 A JP2010522982 A JP 2010522982A JP 2010537990 A5 JP2010537990 A5 JP 2010537990A5
Authority
JP
Japan
Prior art keywords
administered
item
combination
antagonist
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537990A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/064232 external-priority patent/WO2009029308A1/en
Publication of JP2010537990A publication Critical patent/JP2010537990A/ja
Publication of JP2010537990A5 publication Critical patent/JP2010537990A5/ja
Pending legal-status Critical Current

Links

JP2010522982A 2007-08-27 2008-05-20 アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ Pending JP2010537990A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96626507P 2007-08-27 2007-08-27
PCT/US2008/064232 WO2009029308A1 (en) 2007-08-27 2008-05-20 Medication combinations for the treatment of alcoholism and drug addiction

Publications (2)

Publication Number Publication Date
JP2010537990A JP2010537990A (ja) 2010-12-09
JP2010537990A5 true JP2010537990A5 (https=) 2011-06-30

Family

ID=40387675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522982A Pending JP2010537990A (ja) 2007-08-27 2008-05-20 アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ

Country Status (4)

Country Link
US (1) US20110065628A1 (https=)
JP (1) JP2010537990A (https=)
CA (1) CA2697990A1 (https=)
WO (1) WO2009029308A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
PL2255184T3 (pl) 2008-02-28 2013-12-31 Univ Virginia Patent Foundation Gen transportera serotoniny i leczenie alkoholizmu
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
RU2436573C2 (ru) * 2009-07-27 2011-12-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт психического здоровья Сибирского отделения Российской академии медицинских наук (НИИПЗ СО РАМН) Способ реабилитации больных алкоголизмом
RU2402352C1 (ru) * 2009-08-13 2010-10-27 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) Способ угнетения алкогольной мотивации
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
PL2801625T3 (pl) 2010-07-02 2018-06-29 University Of Virginia Patent Foundation Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
EP3045173A3 (en) 2011-09-09 2016-09-14 The University of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
RU2495679C1 (ru) * 2012-07-16 2013-10-20 Станислав Анатольевич Кедик Имплант на основе дисульфирама для лечения пациентов, зависимых от алкоголя или опиатов
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
US20140161879A1 (en) * 2012-07-31 2014-06-12 Zogenix, Inc. Treating pain in patients with hepatic impairment
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
KR102597910B1 (ko) 2015-03-26 2023-11-02 재클린 엠. 이베르센 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물
WO2016160715A1 (en) * 2015-03-27 2016-10-06 Markel Dan Method for treating addiction
KR102634829B1 (ko) * 2016-06-24 2024-02-07 오피언트 파마슈티컬스, 인코퍼레이티드 알코올 사용 장애의 치료용 조성물, 장치 및 방법
RU2629529C1 (ru) * 2016-08-09 2017-08-29 Ольга Ивановна Салмина-Хвостова Способ лечения алкоголизма
RU2629530C1 (ru) * 2016-08-12 2017-08-29 Ольга Ивановна Салмина-Хвостова Способ лечения алкогольной зависимости
IL312012A (en) 2016-11-18 2024-06-01 Opiant Pharmaceuticals Inc Compositions and methods for the treatment of opioid overdose
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
WO2019038687A1 (en) * 2017-08-22 2019-02-28 Euphoria Beer Development Ltd ENRICHED ALCOHOLIC BEVERAGES
KR20200085730A (ko) 2017-09-07 2020-07-15 엔엘에스-1 파마 아게 헤로인 의존성 및 물질 사용 장애에 대한 마진돌 치료
US11160843B2 (en) * 2018-04-30 2021-11-02 Yale University Oxytocin and opioid antagonists for treatment of social dysfunction disorder
AU2019403368A1 (en) * 2018-12-20 2021-07-29 Aegis Therapeutics, Llc Compositions, devices, and methods for the treatment of overdose and reward-based disorders
RU2721606C1 (ru) * 2019-11-08 2020-05-21 Общество с ограниченной ответственностью "Ай Кью Витаминная студия" Фармацевтическая композиция для парентерального капельного введения
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders
JP2024521754A (ja) * 2021-05-25 2024-06-04 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性
MX2024001659A (es) 2021-08-04 2024-06-26 Indivior Inc Composiciones y métodos para el tratamiento de la sobredosis por opioides.
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
EP4588477A1 (en) * 2023-12-01 2025-07-23 Shenzhen Sciencare Pharmaceutical Co., Ltd. Pharmaceutical composition for preventing cannabis relapse and use thereof
WO2025207125A1 (en) * 2024-03-26 2025-10-02 The Regents Of The University Of California Combination pharmacological interventions for obstructive sleep apnea

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550021A (en) * 1990-02-07 1996-08-27 Board Of Regents, The University Of Texas System Allelic diagnosis of susceptibility to compulsive disorder
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US20040167164A1 (en) * 1998-05-05 2004-08-26 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
WO2002026118A2 (en) * 2000-09-29 2002-04-04 New Health Sciences, Inc. Systems and methods for assessing vascular effects of a treatment
US7122308B2 (en) * 2001-02-16 2006-10-17 Centre For Addiction And Mental Health Detection of antidepressant induced mania
US7033771B2 (en) * 2001-05-08 2006-04-25 Takeda Pharmaceutical Company Limited Use of insulin response modulators in the treatment of diabetes and insulin resistance
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
WO2003018843A1 (en) * 2001-08-21 2003-03-06 Smithkline Beecham Corporation Gene polymorphisms and response to treatment
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
HUE034290T2 (en) * 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7163969B2 (en) * 2003-10-14 2007-01-16 Stockhausen, Inc. Superabsorbent polymer aqueous paste and coating
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
CA2623072A1 (en) * 2005-09-26 2007-04-05 Avigen, Inc. Use of ibudilast for treating drug and behavioral addictions
US20070292880A1 (en) * 2006-05-05 2007-12-20 Robert Philibert Compositions and methods for detecting predisposition to a substance use disorder or to a mental illness or syndrome
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2010513569A (ja) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール摂取に対するトピラメートおよびオンダンセトロンの併用効果
US20100076006A1 (en) * 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
US20080228700A1 (en) * 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
US20110264374A1 (en) * 2007-08-21 2011-10-27 University Of Virginia Patent Foundation Method, Computer Program Product and System for Individual Assessment of Alcohol Sensitivity
PL2255184T3 (pl) * 2008-02-28 2013-12-31 Univ Virginia Patent Foundation Gen transportera serotoniny i leczenie alkoholizmu
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2425013A1 (en) * 2009-05-01 2012-03-07 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism

Similar Documents

Publication Publication Date Title
JP2010537990A5 (https=)
JP2010513569A5 (https=)
Aveline et al. Postoperative analgesia and early rehabilitation after total knee replacement: a comparison of continuous low-dose intravenous ketamine versus nefopam
US8012958B2 (en) Methods for treating anxiety related disorders
CN101534809B (zh) 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途
Anton et al. Current pharmacotherapies of alcoholism: a US perspective
US20150352107A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
O'Rourke et al. Preoperative management of opioid and nonopioid analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement
JP2011515076A5 (https=)
Londhe et al. Efficacy and safety of buprenorphine transdermal patch for immediate postoperative analgesia after total knee arthroplasty surgery
US20080175903A1 (en) Treatment of anxiety with eszopiclone
Teegarden et al. 5-HT2A inverse-agonists for the treatment of insomnia
US20220023316A1 (en) Methods for the treatment of depression
US11382869B2 (en) Dextromethorphan transdermal delivery device
CA2450787C (en) Active ingredient combination for pharmacological addictive substance or intoxicant therapy
CN100386070C (zh) 包含褪黑激素的药物制剂
US8242132B2 (en) Methods and compositions for alleviating stuttering
Kumar et al. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients
CN110191706A (zh) 治疗利多卡因无效病症和低钾血病症的治疗方法
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
AU2023356341A1 (en) Transdermal delivery of dextromethorphan
HK40129313A (zh) 右美沙芬的经皮递送
UA79752C2 (en) Active substance combination for medicamentous therapy of nicotine dependency, method of treatment
Prescilla The pharmacology and clinical application of sedatives, analgesics, and adjuncts
PATEL ACUTE AND CHRONIC PAIN